These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 33748410)

  • 21. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction.
    Sato M; Waddell TK; Wagnetz U; Roberts HC; Hwang DM; Haroon A; Wagnetz D; Chaparro C; Singer LG; Hutcheon MA; Keshavjee S
    J Heart Lung Transplant; 2011 Jul; 30(7):735-42. PubMed ID: 21419659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Effect of Monthly Anti-CD25
    Ross DJ; Belperio J; Natori C; Ardehali A
    Int J Organ Transplant Med; 2020; 11(3):101-106. PubMed ID: 32913585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of chronic lung allograft dysfunction, especially restrictive allograft syndrome, on the survival after living-donor lobar lung transplantation compared with cadaveric lung transplantation in adults: a single-center experience.
    Sugimoto S; Yamamoto H; Kurosaki T; Otani S; Okazaki M; Yamane M; Toyooka S; Oto T
    Surg Today; 2019 Aug; 49(8):686-693. PubMed ID: 30790054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lung microbiota predict chronic rejection in healthy lung transplant recipients: a prospective cohort study.
    Combs MP; Wheeler DS; Luth JE; Falkowski NR; Walker NM; Erb-Downward JR; Lama VN; Dickson RP
    Lancet Respir Med; 2021 Jun; 9(6):601-612. PubMed ID: 33460570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk assessment of chronic lung allograft dysfunction phenotypes: Validation and proposed refinement of the 2019 International Society for Heart and Lung Transplantation classification system.
    Levy L; Huszti E; Renaud-Picard B; Berra G; Kawashima M; Takahagi A; Fuchs E; Ghany R; Moshkelgosha S; Keshavjee S; Singer LG; Tikkanen J; Martinu T
    J Heart Lung Transplant; 2020 Aug; 39(8):761-770. PubMed ID: 32418864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significance of phenotype change after chronic lung allograft dysfunction onset.
    Fuchs E; Levy L; Huszti E; Renaud-Picard B; Berra G; Kawashima M; Takahagi A; Ghany R; Havlin J; McInnis MC; Keshavjee S; Singer LG; Tikkanen J; Chow CW; Martinu T
    Transpl Int; 2021 Dec; 34(12):2620-2632. PubMed ID: 34748217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of extracorporeal photopheresis and alemtuzumab for the treatment of chronic lung allograft dysfunction.
    Moniodis A; Townsend K; Rabin A; Aloum O; Stempel J; Burkett P; Camp P; Divo M; El-Chemaly S; Mallidi H; Rosas I; Fuhlbrigge A; Koo S; Goldberg HJ
    J Heart Lung Transplant; 2018 Mar; 37(3):340-348. PubMed ID: 28431983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Basiliximab as an alternative to antithymocyte globulin for early immunosuppression in lung transplantation.
    Clinckart F; Bulpa P; Jamart J; Eucher P; Delaunois L; Evrard P
    Transplant Proc; 2009 Mar; 41(2):607-9. PubMed ID: 19328937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal lung function measurements in single lung transplant recipients with chronic lung allograft dysfunction.
    Leuschner G; Lauseker M; Howanietz AS; Milger K; Veit T; Munker D; Schneider C; Weig T; Michel S; Barton J; Meiser B; Dinkel J; Neurohr C; Behr J; Kneidinger N
    J Heart Lung Transplant; 2020 Nov; 39(11):1270-1278. PubMed ID: 32917480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of gram negative bacteria airway recolonization on the occurrence of chronic lung allograft dysfunction after lung transplantation in a population of cystic fibrosis patients.
    Orfanos S; Gomez C; Baron S; Akkisetty R; Dufeu N; Coltey B; Thomas PA; Rolain JM; Reynaud-Gaubert M
    BMC Microbiol; 2018 Aug; 18(1):88. PubMed ID: 30126365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party.
    Marsh J; Schrezenmeier H; Marin P; Ilhan O; Ljungman P; McCann S; Socie G; Tichelli A; Passweg J; Hows J; Raghavachar A; Locasciulli A; Bacigalupo A
    Blood; 1999 Apr; 93(7):2191-5. PubMed ID: 10090926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of total lymphoid irradiation for chronic allograft rejection following bilateral lung transplantation.
    Diamond DA; Michalski JM; Lynch JP; Trulock EP
    Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):795-800. PubMed ID: 9652840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bronchoalveolar lavage cytokine-based risk stratification of minimal acute rejection in clinically stable lung transplant recipients.
    Levy L; Huszti E; Ahmed M; Ghany R; Hunter S; Moshkelgosha S; Zhang CYK; Boonstra K; Klement W; Tikkanen J; Singer LG; Keshavjee S; Juvet S; Martinu T
    J Heart Lung Transplant; 2021 Dec; 40(12):1540-1549. PubMed ID: 34215500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Azithromycin prophylaxis after lung transplantation is associated with improved overall survival.
    Li D; Duan Q; Weinkauf J; Kapasi A; Varughese R; Hirji A; Lien D; Meyer S; Laing B; Nagendran J; Halloran K
    J Heart Lung Transplant; 2020 Dec; 39(12):1426-1434. PubMed ID: 33041181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional and computed tomographic evolution and survival of restrictive allograft syndrome after lung transplantation.
    Verleden SE; de Jong PA; Ruttens D; Vandermeulen E; van Raemdonck DE; Verschakelen J; Vanaudenaerde BM; Verleden GM; Vos R
    J Heart Lung Transplant; 2014 Mar; 33(3):270-7. PubMed ID: 24461432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Impact of Inadequate ("AX") Transbronchial Biopsies on Post-lung Transplant CLAD or Death.
    Levy L; Huszti E; Pal P; Tikkanen J; Ghany R; Keshavjee S; Martinu T; Singer LG
    Transplantation; 2021 Feb; 105(2):390-395. PubMed ID: 32150039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction.
    Iasella CJ; Ensor CR; Marrari M; Mangiola M; Xu Q; Nolley E; Moore CA; Morrell MR; Pilewski JM; Sanchez PG; McDyer JF; Zeevi A
    J Heart Lung Transplant; 2020 Dec; 39(12):1417-1425. PubMed ID: 32981841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Importance of the preoperative prognostic nutritional index score as a predictor of chronic lung allograft dysfunction after lung transplantation: a Japanese single-institution study.
    Kanou T; Minami M; Funaki S; Ose N; Fukui E; Kimura K; Shintani Y
    Surg Today; 2021 Dec; 51(12):1946-1952. PubMed ID: 33839934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COMP: A Potential Early Biomarker of RAS After Lung Transplantation.
    Novo M; Westin J; Andersson LM; Jonsson Berdenius A; Nordén R; Magnusson JM
    Transplant Direct; 2021 Aug; 7(8):e730. PubMed ID: 34291152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.